July 25, 2008 - The cardiac transplant team from St. Vincent’s Hospital in Sydney, Australia, will travel to Paris July 28-29 to begin the first phase of certification training for the CardioWest temporary total artificial heart (TAH-t).
“We are very excited to be the first hospital in Australia,” said Dr. Paul Jansz, cardiothoracic and transplant surgeon at St. Vincent’s. “As the future CardioWest training center for the Asia-Pacific region, we look forward to expanding the use of this life-saving technology at our hospital and other top transplant hospitals in Australia and New Zealand.”
St. Vincent’s will be the 35th hospital in the world to complete the first phase of certification training. Since performing Australia’s first heart transplant in 1968, St. Vincent’s has been on the cutting edge of cardiac surgery. The hospital’s current one-year survival rate for heart transplant is 95 percent, compared to 86 percent in the U.S. in 2007 (American Heart Association).
The CardioWest artificial heart is the first and only FDA, Health Canada and CE Mark approved temporary total artificial heart. There have been more than 740 implants of the CardioWest, the company said.
For more information: http://syncardia.com